The investigational vaccine that KPWHRI’s team first tested shows an efficacy rate of about 94% as research continues.
In a Viewpoint for JAMA, KPWHRI’s Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.